Sponsored Videos

Biomanufacturing has relied on largely unchanged processes for decades, but today’s complex molecules require a smarter approach. Sundar Ramanan, PhD, MBA, Chief Quality Officer at Enzene, explains how fully-connected continuous manufacturing™ (FCCM™) enables this shift by integrating real-time monitoring, automation, and contamination control.

A new partnership between MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, and Simtra BioPharma Solutions is delivering streamlined ADC solutions that simplify the supply chain, accelerate patient access to vital treatments, and offer customers expert support.

Rentschler Biopharma is evolving its CDMO capabilities through strategic partnerships, infrastructure investments, and sustainability initiatives to better support clients' complex biologics programs.

Steve Griffiths, Global VP of Business Development at GCS, discusses the essential environmental factors involved in cleanroom construction. Viewers will gain insight into the decisions that influence sustainability from selecting materials to optimizing energy use.

Christine S. Yore of Ecolab discusses products and solutions that help pharmaceutical companies address sustainability and cost challenges, along with other key issues in today’s market.

Innovative Fully-Connected Continuous Manufacturing™ technology and advanced facilities are revolutionizing biomanufacturing and driving cost efficiency, especially in monoclonal antibody production.

Christiane Bardroff, Chief Operating Officer and Patrick Meyer Global Head of Business Development—both at Rentschler Biopharma SE—share their insights into the company’s client-centric approach.

Benedikt von Braunmühl, CEO of Rentschler Biopharma, discusses the company's strategic shift toward biologics CDMO services.

Dr Himanshu Gadgil, CEO, Enzene Biosciences Ltd., describes the rationale for expanding its services, including its patented EnzeneX™ continuous manufacturing technology platform, to emerging innovative, US-based biotech firms looking to benefit from the in-depth expertise in continuous manufacturing.

Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.

In this interview, Jakob Liderfelt, Product Manager at Cytiva, discusses main challenges faced during chromatography process development for mAbs and mAb variants such as fragments and bispecific antibodies. Then, he shares his top tips for addressing challenges associated with mAb aggregates removal and separation of homo and heterodimers.

Matthew McClorey, President of CritiTech Particle Engineering Solutions, shares his insights at AAPS.

In silico process development for chromatography is a paradigm-shifting approach that redefines the routine work of process development scientists. But what does it actually mean to perform process development in silico? Do I need to be a math expert? Where is modeling applicable? Will I not set foot in the lab ever again?

In this video, Emma Lind, Product Manager for Chromatography Resins at Cytiva answers questions from BioPharm International about the challenges faced by process developers working with recombinant proteins.

Zachary Welch, Parker Bioscience, highlights single-use bioprocessing solutions presented at INTERPHEX 2022. Watch this video for insight regarding:

Let us take you on a behind the scenes tour of our 260,000 sq. ft. manufacturing facility in College Station, TX and a glimpse of our 120,000 sq. ft. facility in Kilkenny, Ireland.

Give a quick overview of the oligonucleotide market, what is happening. Cover the typical challenges with oligonucleotide synthesis in the process development phase and solutions for those. Key considerations when scaling up oligonucleotide synthesis

Innovation has brought about a diversification of therapeutics molecules. In this discovery interview we will explore what mechanistic modelling is and how you can use it to develop these diverse therapeutics and what challenges this brings to the future of your process development.

G-CON is fulfilling the needs of reliable and fast deliverable capacities for the biopharmaceutical industry. Through a well-defined customer needs driven approach to design, production, installation and qualification, G-CON provides a fully functional cleanroom product portfolio enabling reliable biocapacity planning on-time and within-budget.

Discover how we make our best-in-class agarose chromatography resins using our patented manufacturing technology Jetting.